1. Health

Discuss in my forum

Carol Eustice

Xeljanz (tofacitinib) Approved by FDA for Rheumatoid Arthritis

By November 7, 2012

Follow me on:

We have been following the development of tofacitinib for some time. In August, we reported that the FDA had pushed back their decision on the New Drug Application to November. On November 6, 2012, the FDA announced it has approved the drug for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. Tofacitinib, which is manufactured by Pfizer, has been given the brand name Xeljanz.

Xeljanz (tofacitinib), classified as a JAK inhibitor, can be taken alone or in combination with methotrexate or other non-biologic DMARDs. Xeljanz should not be used with biologic drugs. It also should not be used with azathioprine or cyclosporine. Check back soon for more information about Xeljanz.

Related Articles:

Follow Me:

Facebook | Twitter | Message Board | Newsletter

Photo by David Sucsy (iStockphoto)

Comments
December 10, 2012 at 5:32 pm
(1) BostonSt says:

Thanks for the information Carol, this is a major innovation for the treatment of RA. Given compliance issues for therapies requiring injections, I believe this new orally dosed drug will help a lot of people.

Leave a Comment

Line and paragraph breaks are automatic. Some HTML allowed: <a href="" title="">, <b>, <i>, <strike>

©2014 About.com. All rights reserved.

We comply with the HONcode standard
for trustworthy health
information: verify here.